- Home
- DV vs AKRO Comparison
DV vs AKRO Comparison
Compare DV & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DV
- AKRO
- Stock Information
- Founded
- DV 2008
- AKRO 2017
- Country
- DV United States
- AKRO United States
- Employees
- DV N/A
- AKRO N/A
- Industry
- DV Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- DV Technology
- AKRO Health Care
- Exchange
- DV Nasdaq
- AKRO Nasdaq
- Market Cap
- DV 3.0B
- AKRO 2.4B
- IPO Year
- DV 2021
- AKRO 2019
- Fundamental
- Price
- DV $19.13
- AKRO $28.09
- Analyst Decision
- DV Buy
- AKRO Strong Buy
- Analyst Count
- DV 18
- AKRO 7
- Target Price
- DV $25.53
- AKRO $43.20
- AVG Volume (30 Days)
- DV 2.7M
- AKRO 617.2K
- Earning Date
- DV 11-06-2024
- AKRO 11-08-2024
- Dividend Yield
- DV N/A
- AKRO N/A
- EPS Growth
- DV 18.39
- AKRO N/A
- EPS
- DV 0.38
- AKRO N/A
- Revenue
- DV $638,459,000.00
- AKRO N/A
- Revenue This Year
- DV $19.75
- AKRO N/A
- Revenue Next Year
- DV $14.34
- AKRO N/A
- P/E Ratio
- DV $50.57
- AKRO N/A
- Revenue Growth
- DV 19.57
- AKRO N/A
- 52 Week Low
- DV $16.12
- AKRO $14.41
- 52 Week High
- DV $43.00
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- DV 56.70
- AKRO 38.58
- Support Level
- DV $16.79
- AKRO $31.12
- Resistance Level
- DV $20.62
- AKRO $35.11
- Average True Range (ATR)
- DV 0.79
- AKRO 1.99
- MACD
- DV 0.19
- AKRO -0.53
- Stochastic Oscillator
- DV 61.10
- AKRO 11.68
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. The DV Authentic Ad ensures that a digital ad was delivered in a brand-safe setting, completely viewable, by a real individual, and in the expected geography, is one of its solutions. It generates revenues from its advertisement customers by charging a Measured Transaction Fee on the volume of Media Transactions Measured on the software platform.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.